| (Values in U.S. Thousands) | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sep, 2023 |
| Sales | 1,001,600 | 929,170 | 751,650 | 634,410 | 781,310 |
| Sales Growth | +7.80% | +23.62% | +18.48% | -18.80% | +31.26% |
| Net Income | -121,350 | -120,410 | -251,150 | -367,550 | 215,410 |
| Net Income Growth | -0.78% | +52.06% | +31.67% | -270.63% | +156.52% |
Beigene Ltd ADR (BGNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.